非小细胞肺癌患者放射性125I粒子植入治疗后近期血清肿瘤标志物变化

  目的   测定放射性粒子植入治疗前后患者血清癌胚抗原（CEA）、糖类抗原125（CA125）、鳞状细胞癌相关抗原（SCC-Ag）、细胞角蛋白19片段（CYFRA21-1）等肿瘤标志物水平，通过比对其动态变化，观察125I粒子植入治疗非小细胞肺癌的疗效与肿瘤标志物水平的关系。   方法   选取自2009年1月至2012年6月在天津医科大学第三医院接受治疗的经病理明确诊断为非小细胞肺癌患者72例，对全部患者行CT引导下放射性125I粒子植入治疗。分别于术前3 d及术后1、2、3、6个月取患者空腹静脉血，送检测定血清肿瘤标志物水平。   结果   125I粒子植入1个月后，肺癌患者血清中CEA、CA125、SCC-Ag、CYFRA21-1等肿瘤标志物较植入前即出现明显变化（P < 0.01）。125I粒子植入后1、2、3、6个月上述肿瘤标志物水平各组间比较无明显差异。   结论   125I粒子植入治疗肺癌能够有效的降低多项肿瘤标志物的水平，不同疗效分级患者的肿瘤标志物水平明显不同。 

Recent changes in serum tumor markers in non-small cell lung cancer patients after radioactive 125I seeds implantation

  Objective   This study aimed to observe the clinical efficacy of implanting radioactive 125I seeds to treat non-small cell lung cancer (NSCLC) on the basis of the recent changes in serum tumor markers (including CEA, CA125, SCC-Ag, and CYFRA21-1).   Methods   We selected 72 patients who were pathologically confirmed with NSCLC and received CT-guided percutaneous implantation of radioactive 125I seeds from January 2009 to June 2012. The concentration of the serum tumor markers was detected 3 d before implantation and 1, 2, 3, and 6 months after implantation.   Results   All of the operations were successfully completed. One month after implantation, a significant change was observed in the concentration of serum tumor markers (CEA, CA125, SCC-Ag, and CYFRA21-1) compared with their preoperative levels (P < 0.01). No significant difference was observed between the different time points after implantation.   Conclusion   The treatment of NSCLC by implanting radioactive 125I seeds can effectively reduce the level of tumor markers. A significant difference was observed in the level of tumor markers between patients with different efficacy classifications.